Tinidazole-Akri® (Tablets) Instructions for Use
Marketing Authorization Holder
Akrikhin Chemical and Pharmaceutical Plant, JSC (Russia)
ATC Code
P01AB02 (Tinidazole)
Active Substance
Tinidazole (Rec.INN registered by WHO)
Dosage Form
| Tinidazole-Akri® | Film-coated tablets, 500 mg: 4 pcs. |
Dosage Form, Packaging, and Composition
Film-coated tablets white or white with a creamy or grayish tint, round, biconvex; on the break – white with a yellowish or yellowish-greenish tint.
| 1 tab. | |
| Tinidazole | 500 mg |
Excipients: pregelatinized starch, sorbitol, potato starch, talc, stearic acid.
Shell composition: hypromellose (hydroxypropyl methylcellulose), macrogol (polyethylene glycol 6000), glycerol (glycerin), titanium dioxide, talc, or a ready-made mixture of white Opadry (hypromellose, titanium dioxide, talc, glycerol (glycerin), macrogol 6000), or a ready-made mixture of white VIVACOAT (hypromellose, titanium dioxide, talc, glycerol (glycerin), macrogol 6000).
4 pcs. – blister packs (1) – cardboard packs.
Clinical-Pharmacological Group
Antiprotozoal drug with antibacterial activity
Pharmacotherapeutic Group
Antimicrobial and antiprotozoal agent
Pharmacological Action
Antiprotozoal agent with antibacterial action. The mechanism of action is due to the inhibition of synthesis and damage to the DNA structure of pathogens.
Active against Trichomonas vaginalis, Entamoeba histolytica, Lamblia intestinalis. It has a bactericidal effect against the following anaerobic bacteria: Bacteroides spp. (including Bacteroides fragilis, Bacteroides melaninogenicus), Clostridium spp., Eubacterium spp., Fusobacterium spp., Peptococcus spp., Peptostreptococcus spp., Veillonella spp.
Pharmacokinetics
Tinidazole has a high degree of absorption, bioavailability is about 100%. Plasma protein binding is 12%. Cmax after oral administration of a 2 g dose is reached after 2 hours and is 40-51 µg/ml, after 24 hours it is 11-19 µg/ml, after 72 hours – 1 µg/ml. Vd – 50 l. Penetrates the blood-brain barrier and placental barrier. Excreted in breast milk within 72 hours after administration.
Metabolized in the liver to form pharmacologically active hydroxylated derivatives that inhibit the growth of anaerobic microorganisms and may enhance the effect of tinidazole. T1/2 – 12-14 hours. 50% is excreted in the bile, 25% is excreted by the kidneys (unchanged) and 12% (as metabolites) due to reabsorption in the renal tubules.
Indications
Trichomoniasis, giardiasis, amebiasis (including hepatic form), infections caused by anaerobic bacteria, mixed aerobic-anaerobic infections (in combination with antibiotics), eradication of Helicobacter pylori (in combination with bismuth preparations and antibiotics).
Prevention of postoperative anaerobic infections.
ICD codes
| ICD-10 code | Indication |
| A06 | Amebiasis |
| A07.1 | Giardiasis |
| A59 | Trichomoniasis |
| B98.0 | Helicobacter pylori as the cause of diseases classified elsewhere |
| K25 | Gastric ulcer |
| K26 | Duodenal ulcer |
| T79.3 | Posttraumatic wound infection, not elsewhere classified |
| Z29.8 | Other specified prophylactic measures |
| ICD-11 code | Indication |
| 1A31 | Giardiasis |
| 1A36.Z | Amoebiasis, unspecified |
| 1A92 | Trichomoniasis |
| DA60.Z | Gastric ulcer, unspecified |
| DA63.Z | Duodenal ulcer, unspecified |
| NF0A.3 | Posttraumatic wound infection, not elsewhere classified |
| QC05.Z | Prophylactic measures, unspecified |
| XN3DY | Helicobacter pylori (H. pylori) |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Determine the dose, regimen, and duration individually based on indication, patient age, and body weight.
For trichomoniasis, administer a single 2 g dose or 150 mg twice daily for 7 days.
For giardiasis, administer a single 2 g dose.
For intestinal amebiasis, administer 2 g daily for 2-3 days.
For amebic liver abscess, administer 1.5-2 g daily for 3-6 days.
For anaerobic bacterial infections, administer an initial 2 g dose, followed by 1 g daily for 5-6 days.
For Helicobacter pylori eradication, administer 500 mg twice daily for 7 days as part of combination therapy.
For surgical prophylaxis, administer a single 2 g dose 12 hours pre-operatively.
Take tablets during or after meals to minimize gastrointestinal discomfort.
Complete the full prescribed course of therapy even if symptoms improve.
For pediatric patients over 12 years, use adult dosages; the drug is contraindicated for children under 12.
Adjust dosage in patients with severe hepatic impairment; monitor plasma concentrations if necessary.
Adverse Reactions
From the digestive system: anorexia, dry oral mucosa, metallic taste in the mouth, nausea, vomiting, diarrhea.
From the nervous system: headache, dizziness, fatigue, impaired coordination of movements (including locomotor ataxia), dysarthria, peripheral neuropathy; rarely – convulsions.
Allergic reactions: urticaria, skin itching, skin rash, angioedema.
Other: transient leukopenia, weakness.
Contraindications
Hypersensitivity to tinidazole or other 5-nitroimidazole derivatives; organic diseases of the central nervous system, blood disorders; first trimester of pregnancy, lactation period (breastfeeding); children under 12 years of age.
Use in Pregnancy and Lactation
Contraindicated for use in the first trimester of pregnancy. Use in the second and third trimesters is possible only in cases where the intended benefit to the mother outweighs the potential risk to the fetus.
If it is necessary to use during lactation, the issue of discontinuing breastfeeding should be decided. Tinidazole is detected in breast milk within 72 hours after administration.
Pediatric Use
Contraindicated for use in children under 12 years of age.
Special Precautions
When treating trichomoniasis, simultaneous treatment of both partners should be carried out.
If adverse reactions from the central nervous system appear, Tinidazole should be discontinued.
During the use of tinidazole, alcohol consumption should be avoided.
When using tinidazole, dark coloration of urine is observed.
If treatment continues for more than 6 days, regular monitoring of the peripheral blood picture should be carried out.
Effect on the ability to drive vehicles and mechanisms
During treatment with tinidazole, patients should refrain from engaging in potentially hazardous activities that require increased attention and high speed of psychomotor reactions.
Drug Interactions
With simultaneous use, Tinidazole enhances the effect of indirect anticoagulants.
Tinidazole is compatible with sulfonamides and antibiotics (aminoglycosides, erythromycin, rifampicin, cephalosporins).
With simultaneous use with ethanol, the development of a disulfiram-like effect cannot be excluded.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Mildronate capsules 500mg, 90pcs
Belosalic, ointment, 30g
No-spa pills 40mg, 64pcs
Actovegin pills 200mg, 50pcs
Cortexin, 10mg, 5ml, 10pcs
Belosalic, lotion solution for external use spray 100ml
Daivobet, ointment, 30g
Kagocel pills 12mg, 30pcs
Picamilon pills 50mg, 60pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Ingavirin capsules 90mg, 10pcs
Fenotropil pills 100mg, 60pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs
Nootropil pills 800mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Noopept, pills 10mg, 50pcs
Arbidol, capsules 100mg, 40pcs 